ArticleResearch square2026
Prevalent versus incident progressive supranuclear palsy: An analysis of the frequencies of neuropathological and clinical features at U.S. Alzheimer's Disease Research Centers indicate a relatively common tauopathy of aging.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Progressive supranuclear palsy (PSP) is a neurodegenerative disease diagnosed according to its histopathologic pattern of tau proteinopathy ("tauopathy"). It is increasingly appreciated that PSP is heterogeneous in both clinical and pathological presentations. However, the prevalence of PSP subtypes, in comparison to other tauopathies, remain incompletely characterized. Here we analyzed NACC Neuropathology Data Set data aggregated from 37 U.S. Alzheimer's Disease Research Centers (ADRCs). Clinical and gold-standard neuropathologic features of autopsied participants were compared, stratifying on cognitive status at recruitment into the study. The final sample comprised 6994 individuals who were followed approximately annually for 4.0 years on average before autopsy. Among those with dementia at recruitment (n=4309), 2.9% had autopsy-confirmed corticobasal degeneration (CBD), 2.6% Pick's disease, and 4.6% PSP. By contrast, among those recruited while cognitively normal (n=1452), 0.7% had CBD, 0.1% Pick's disease, and, remarkably, 3.3% were diagnosed with PSP pathology. The relatively high frequency of PSP pathology detected among individuals recruited while cognitively normal suggests there is a subtype of PSP that is unexpectedly common in the broader population. In comparing between incident (recruited normal) and prevalent (recruited with dementia) autopsy-confirmed PSP, those with incident PSP died older (89.6 years versus 76.2 years on average). Furthermore, incident PSP pathology cases were less likely to manifest stereotypical PSP clinical features, but more likely to have parkinsonism, compared to prevalent PSP pathology cases. In a convenience sample of autopsy-confirmed PSP from the University of Kentucky ADRC (n=23), digital pathology analyses using HALO software and AI-based analytic modules revealed that PSP tau pathology was more severe in prevalent PSP, but in the putamen, incident cases had a higher proportion of tufted astrocytes and lower proportion of NFTs. In summary, incident PSP pathology is a relatively common tauopathy in older ADRC participants, often differing clinically and pathologically from prevalent PSP.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.